MVIS US Listed Biotech 25 Index

The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that generate at least 50% of their revenues from biotechnology. The pure-play index contains only companies which are engaged primarily in research and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. The MVIS US Listed Biotech 25 Index (MVBBH) has been licensed to underlie financial products with currently USD 497.4 million in assets under management.

Financial Products

A licence agreement is required to use our indices, index data or trademark for any commercial purpose, or for research and analysis, or for the issuance, launch, promotion or marketing of financial products such as exchange-traded products, mutual funds, certificates, derivatives, swaps, bonds or OTC products linked to or based on MVIS indices. Please contact us for information on obtaining a licence.

The MVIS US Listed Biotech 25 Index Index is currently licensed to underlie the following products:

  • VanEck Vectors Biotech ETF